Teva/Active Biotech Initiate Phase III Program For Laquinimod Oral MS Therapy
This article was originally published in The Pink Sheet Daily
Executive Summary
Firm enters Phase III along with Acorda, Biogen Idec, others in race to bring first oral MS agent to market.